PDL Pulls The Plug On Nuvion Program After Phase III Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Interim analysis from a Phase III study of the investigational ulcerative colitis therapy shows insufficient efficacy and an inferior safety profile, company reports.